Angiotensin-converting enzyme inhibitors in adults with cyanotic congenital heart disease

In carefully selected patients with cyanotic congenital heart defects, the response to systemic afterload reduction with ACE inhibitors appears favorable. A more comprehensive controlled trial to assess the hemodynamic and functional effects of ACE inhibitors in such patients should be undertaken.